Luis Calderón – General Manager, Alexion Mexico
Mexico is improving its regulatory framework for orphan drugs. The general manager of Alexion Mexico explains how the company is working with the authorities to ensure adequate regulation is put…
Alexion is a global biopharmaceutical company that combines groundbreaking science with a steadfast commitment to meeting the needs of patients living with severe, life-threatening and often ultra-rare diseases. Alexion scientists are among the first in the world to unlock the therapeutic potential of inhibiting terminal complement, a group of proteins that play an important role in the body’s immune response and can destroy healthy tissue in certain patients. Alexion discovered and developed Soliris® (eculizumab), a first-in-class terminal complement inhibitor, approved in the United States, Canada, European Union, Australia, and Japan as a treatment for patients with paroxysmal nocturnal hemoglobinuria (PNH). Alexion is working urgently to investigate Soliris and additional biopharmaceuticals as treatments for patients with other rare and severe diseases, including cancer.
Contact details
Alexion
Paseo de los Tamarindos 90
Torre 1 Piso 6 Oficina A
Col. Bosque de la Lomas, Del. Cuajimalpa,
C.P. 05120, México DF
MEXICO
Tel: +52 (55) 5047 1500
Website: http://alxn.com/
Mexico is improving its regulatory framework for orphan drugs. The general manager of Alexion Mexico explains how the company is working with the authorities to ensure adequate regulation is put…
Gent Hoxha, founder and CEO of lab equipment specialist Aspelab, explains the company’s growth strategy in Mexico, the intricacies of the Mexican medtech market, and how Aspelab’s solutions enhance both…
Victor Casasola, CEO at Canitec, explains the unique business model of his Mexican medical devices success story, offering an integral service to its clients, and showcases the high added value…
Fausto Hernández, CEO at ValidPro, explains the unique business model of the company as well as the high added value of its qualification and validation services; offering integral solution that…
Martin Ferrari del Sel, country manager at Dräger Mexico, explains the importance of enhancing the efficiency ratios in public and private hospitals, considering the shortage of health infrastructure to cover…
Armando Martínez, general manager at Beckman Coulter Mexico, explains the company’s unique business model Coulter, the strong added-value of its broad and innovative healthcare solutions, and how they help improve…
Abelardo Meneses García, General Director at the National Cancer Institute of Mexico (INCan), explains the evolution of cancer’s footprint in Mexico and showcases how the institute has been investing in…
José Luis Hernández, general manager at Kedrion Mexico, explains the strategy followed by the affiliate in Mexico to obtain success during the past eight years and showcases the added value…
Maarten Pouw, business unit director of Mexico and Latin America at DSM Sinochem Pharmaceuticals, explains the crucial role that sustainable antibiotics play in combating antimicrobial resistance and showcases the company’s…
GM Gerardo Torres-Septién explains how Grupo Rasch has managed to grow during the last two years and showcases the added value of its solutions to help the pharmaceutical industry enhance…
Juan Francisco Hernández, general manager of Latin America at Wockhardt, showcases the added value of the company to the entire region based on quality, safety and cost-effective medicines targeting diabetes,…
María Teresa Lopez, managing director at Zimmer Biomet Mexico, discusses the medtech company’s strong commitment to Mexico as well as the high added value of its broad and innovative health…
Alberto Wicker, CEO at Signufarma, explains how patient compliance programs can enhance the national healthcare system through reducing the cost of treatment as well as improving patients’ quality of life…
See our Cookie Privacy Policy Here
